Back
Impressive Objective Response to Nab-Paclitaxel plus Trastuzumab as Fifth Line Therapy in an Elderly HER-2 Positive Breast Cancer Patient
Maria Rosaria Valerio, Chiara Ancona, Antonella Marchese, Vittorio Gebbia
J. Cancer Ther. Vol.8 No.11, November 16, 2017  DOI: 10.4236/jct.2017.811082
       (PDF  2300K)     HTML      XML
A Case Series of Patients with Pancreatic Cancer and Cholangiocarcinoma Treated with nab-Paclitaxel at a Single Institution
Michael P. Kolinsky, Michael B. Saywer, Jennifer L. Spratlin
J. Cancer Ther. Vol.5 No.6, May 29, 2014  DOI: 10.4236/jct.2014.56069
       (PDF  292K)     HTML     
Treatment with Paclitaxel Orotate and Carboxyamidotriazole Orotate in SC-Implanted OVCAR-5 Human Ovarian Tumor Xenografts
Rashida A. Karmali, Yulia Maxuitenko, Greg Gorman
J. Cancer Ther. Vol.4 No.4, June 04, 2013  DOI: 10.4236/jct.2013.44098
       (PDF  582K)     HTML     
Impact of Oxaliplatin-Induced Neuropathy on Subsequent Paclitaxel for Advanced Gastric Cancer
Jun Sato, Satoru Iwasa, Yoshitaka Honma, Atsuo Takashima, Natsuko Okita, Ken Kato, Tetsuya Hamaguchi, Yasuhide Yamada, Narikazu Boku
Int. J. Clin. Med. Vol.11 No.9, September 17, 2020  DOI: 10.4236/ijcm.2020.119045
       (PDF  509K)     HTML      XML
Long Term Progression Free Survival Achieved by Maintenance “Second–Line” Polychemotherapy with Gemcitabine/Paclitaxel in Metastatic Urothelial Cancer of the Renal Pelvis—A Case Report
Andreas Bannowsky, Hermann Ahlen, Klaus-Peter Jünemann
J. Cancer Ther. Vol.1 No.4, December 31, 2010  DOI: 10.4236/jct.2010.14035
       (PDF  444K)     HTML     
 
 
Top